Reata Reports Positive Results From First-in-Man Study of Cancer Drug
Posted on: Monday, 2 June 2008, 12:22 CDT
Reata Pharmaceuticals has announced promising results from a first-in-man study of RTA 402 in patients with advanced cancers.
The data showed that RTA 402 had an excellent safety profile and provided a clinical benefit in a significant percentage of patients. Investigators also confirmed that the drug was active against its biological targets, NF-kappa B and STAT3. These pro-inflammatory transcription factors promote tumor growth, angiogenesis, invasion, metastasis, and resistance to therapy. Overall, RTA 402 showed a profile of disease control and tumor reduction comparable or superior to any recently approved targeted therapy in a Phase I patient population and a markedly superior side effect profile.
As is standard in the development of cancer drugs, this first-in-man study was conducted in patients with advanced cancers without other treatment options. In this difficult patient population, RTA 402 provided a clinical benefit of tumor regression or stable disease to almost half of the evaluable patients in the study. Two patients, one with mantle cell lymphoma and one with thyroid cancer, experienced 'objective responses' in which their tumors disappeared or shrank significantly following treatment.
Additionally, several patients with refractory, melanoma or renal cell carcinoma saw their tumors stop growing for more than six months. The activity seen with RTA 402 in this study compares favorably with Phase I studies of recently approved, targeted anticancer agents. Additional data from the study suggest that RTA 402 treatment may promote an anti-tumor immune response. Current research by Reata and its collaborators is focused on characterizing these effects in detail.
RTA 402 was exceptionally well tolerated, with a significantly better side effect profile than recently approved agents. With this safety profile, the drug is an excellent candidate for use in combination therapy with other types of cancer therapies, particularly first-line regimens.
Source: Datamonitor
Related Articles
- Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease
- Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
- Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease
- RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- MethylGene Initiates Phase I Clinical Trial for Its Multi-Targeted (C-Met) Kinase Inhibitor, MGCD265, in Solid Tumor Cancers
- Studies of Nipent(R) in Combination Cancer Therapies for Treatment of Chronic Lymphocytic Leukemia and Graft-Versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting
- Alzheimer's patients get less breast cancer therapy
- Biotech Cancer Therapy Gets Approval in China
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
- Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
 |
 |
User Comments (0)
RSS Feeds